证券代码：603030 证券简称：全筑股份 公告编号：2025-034 关于公司最近五年被证券监管部门和证券交易所处罚或 采取监管措施及整改情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海全筑控股集团股份有限公司（以下简称"公司"）于 2025 年 7 月 23 日召 开了第五届董事会第三十次会议、第五届监事会第十八次会议，审议通过了公司 2025 年度以简易程序向特定对象发行股票的相关议案。 鉴于公司拟申请以简易程序向特定对象发行股票，根据中国证券监督管理委员 会相关要求，现将公司最近五年被证券监管部门和交易所采取处罚或监管措施及整 顿情况公告如下： 一、最近五年被证券监管部门和交易所处罚及整改情况 经自查，最近五年，公司不存在被证券监管部门和上海证券交易所处罚的情况。 二、最近五年被证券监管部门和交易所采取监管措施及整改情况 （一） 《关于对上海全筑控股集团股份有限公司及有关责任人予以监管警示的决 定》 《关于 对上海全筑控股集团股份有限公司及有关责任人予以监管警示的决定》，主要内容如 下： "经查明， ...

Core Viewpoint - The stock of NuoTai Bio (688076.SH) was officially changed to "ST NuoTai" following the announcement of a financial fraud case, leading to an 11% drop in stock price on the first trading day after the change [1][2]. Group 1: Financial Fraud Details - NuoTai Bio's financial fraud was revealed in the "Administrative Penalty Notice" issued by the China Securities Regulatory Commission (CSRC), indicating that the company had fabricated financial data in its 2021 annual report [2][3]. - The fraudulent activity involved a technology transfer to Zhejiang Huabei Pharmaceutical Co., which lacked the financial capability and operational capacity to pay for or utilize the technology, resulting in an inflated revenue of 30 million yuan and an inflated profit of 25.9516 million yuan, accounting for 20.64% of the reported profit [3][4]. - NuoTai Bio also included false financial data in its convertible bond issuance documents, continuing to use the fraudulent 2021 financial figures in its fundraising materials [3]. Group 2: Penalties and Consequences - The CSRC proposed penalties against NuoTai Bio, including a fine of 47.4 million yuan and warnings for the company and its executives, with total penalties amounting to 76.2 million yuan, setting a record for penalties on the STAR Market [4][5]. - The actual controllers of NuoTai Bio, Zhao Dezhong and Zhao Deyi, received fines of 13 million yuan and 5 million yuan respectively, while four senior executives were fined between 1.5 million and 3.3 million yuan [4][5]. Group 3: Role of Nanjing Securities - Nanjing Securities, the sponsor for NuoTai Bio's IPO and convertible bond issuance, is implicated in the fraud due to its confirmation of the accuracy of the financial disclosures in the listing and bond issuance documents [6]. - Nanjing Securities earned approximately 66.3854 million yuan in underwriting fees from the IPO and around 5.66 million yuan from the convertible bond project [6]. - The firm has faced multiple issues with its sponsored projects, including instances of financial fraud and information disclosure violations [7][8].

7月22日， 内蒙古证监局公布的一纸罚单，揭开了内蒙古骑士乳业集团股份有限公司（以下简称"骑士乳业"）在期货市场巨亏却隐瞒不报的违规内幕。该公 司及包括时任董事长党涌涛在内的三名高管因未及时披露重大损失，被处以总计340万元的罚款及警告。该决定书落款日期为2025年7月18日。 经内蒙古证监局查明，骑士乳业2024年开展了豆粕、白糖、尿素等期货交易业务，期间出现重大亏损且未按规定及时披露。 2024年1月17日，公司及其子公司8个期货账户累计亏损达902.46万元，占公司2022年度经审计净利润的12.60%。此重大亏损状态持续至2月27日，期间最高 亏损达1751.37万元，占2022年净利润的24.45%。 2024年7月18日，累计亏损扩大至1294.55万元，占公司2023年度经审计净利润的12.77%。亏损状态持续至7月25日。 2024年8月13日，累计亏损激增至3873.36万元，占2023年度净利润的38.21%。亏损状态持续至年底，期间最高亏损达到4167.88万元，占2023年度净利润的 比例高达41.12%。 内蒙古证监局认定，骑士乳业上述期货交易重大亏损事项可能对公司股票交易价格产生较 ...

证券代码：600692 证券简称：亚通股份 公告编号：2025-020 上海亚通股份有限公司关于收到 上海证监局行政监管措施决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 上海亚通股份有限公司（以下简称"公司"）于近日收到中国证券 监督管理委员会上海监管局（以下简称"上海证监局"）《关于对上海 亚通股份有限公司采取责令改正措施并对梁峻、翟云云、顾培采取出 具警示函措施的决定》 （沪证监决〔2025〕135 号） （以下简称《决定书》 内容如下： 一、 《决定书》的主要内容 上海亚通股份有限公司、梁峻、翟云云、顾培： 经查，上海亚通股份股份有限公司(统一社会信用代码： 规事项： 一是 2023 年 4 月 17 日，上海华盛建设投资控股(集团)有限公司(以 下简称"华盛建设")通过公开招投标中标亚通股份控股子公司上海长 鸿兴通房地产开发有限公司崇明区长兴镇 G9CM-0401 单元 38-07 地块 保障房建设项目的桩基工程(以下简称"长兴桩基工程")。2023 年 4 月 20 日，亚通股份全资子公司上海环岛混 ...

Core Viewpoint - Yibin Paper Industry (600793.SH) faced regulatory penalties due to information disclosure issues during its acquisition of Sichuan Push Acetate Fiber Co., Ltd, highlighting compliance management deficiencies within the company [2][4][6]. Group 1: Acquisition and Financial Performance - In December 2024, Yibin Paper completed the acquisition of 67% of Push Acetate for 206 million yuan, expanding its product offerings to include acetate fiber [2][5]. - Following the acquisition, Yibin Paper's acetate fiber product sales and revenue increased, with a projected net profit of 18.65 million to 22.8 million yuan for the first half of 2025, marking a turnaround from previous losses [2][8]. - In 2024, the acetate fiber segment generated 816 million yuan in revenue, accounting for 36.46% of total revenue, with production and sales volumes increasing year-on-year [5][8]. Group 2: Regulatory Issues - The company received a warning letter from the Sichuan Securities Regulatory Bureau for failing to disclose 191 million yuan in funds that were not timely transferred back to Push Acetate's account during the acquisition process [4][6]. - Key executives, including the chairman and general manager, were held responsible for the disclosure failures, and the company was required to conduct a comprehensive self-examination and submit a rectification report [4][6]. Group 3: Historical Financial Challenges - Yibin Paper experienced consecutive years of losses in its core paper business, with a net loss of 128 million yuan in 2024 and a decline in revenue by 8.34% [6][7]. - The company faced challenges such as rising raw material costs and increased competition in the food paper market, leading to a significant drop in paper product sales and revenue [7][8]. Group 4: Future Outlook - The company anticipates improved profitability in 2025, driven by business structure optimization, cost control measures, and growth in acetate fiber sales [8]. - Despite the positive outlook, significant shareholders have begun to reduce their stakes, indicating potential concerns about the company's long-term performance [8].

Core Viewpoint - Shenzhen Securities Regulatory Bureau issued a warning letter to Shenzhen Shenye Logistics Group Co., Ltd. for failing to disclose its 2024 interim and annual reports on time, violating regulations [1][3]. Group 1: Regulatory Actions - The company has been publicly held accountable for similar issues four times since 2022, indicating a pattern of non-compliance with disclosure requirements [4]. - Previous regulatory actions include a correction order in June 2022 for not timely disclosing the 2021 annual report, a warning letter in March 2024 for the 2022 interim report, and another correction order in May 2024 for the 2023 annual report [4][5]. Group 2: Company Background - Shenzhen Shenye Logistics was established in 1985 and is primarily engaged in road transportation, with a registered capital of 923.45 million RMB [6]. - The company is controlled by Shenzhen Jushenghua Co., Ltd., which holds a 74% stake, and has 34 recorded enforcement actions against it, totaling approximately 22.656 billion RMB [6].

文/梧桐小编 7月18日，内蒙古骑士乳业集团股份有限公司（832786）公告公司及相差人员收到行政处罚决定书。经查， 骑士乳业未按规定及时披露期货交易重大亏损事项。2024年，骑士乳业开展了豆粕、白糖、尿素等期货交 易业务。公司期货交易重大亏损状态持续至2024年12月31日。期间累计亏损金额最高达到4167.88万元，占 骑士乳业2023年度经审计净利润的41.12%。骑士乳业未按规定及时履行信息披露义务。内蒙古证监局决 定：1、对骑士乳业责令改正，给予警告，并处以200万元罚款；2、对党涌涛（实控人、控股股东、董事 长）给予警告，并处以80万元罚款；3、对王喜临（董事、财务负责人）给予警告，并处以40万元罚款； 4、对陈勇（董事、董秘）给予警告，并处以20万元罚款。公司及3名责任人合计被罚款340万元。同一天， 北交所也公布了公司及3名责任人纪律处分的决定。骑士乳业2023年10月13日上市，被称为北交所"乳业上 市第一股"。 违规行为 骑士乳业未按规定及时披露期货交易重大亏损事项。 2024年，骑士乳业开展了豆粕、白糖、尿素等期货交易业务。截至2024年1月17日，骑士乳业及其子公司共 计8个期货账户累 ...

Core Viewpoint - The company Tibet Summit (600338.SH) is facing significant challenges due to its controlling shareholder, Tachen International Resources Co., Ltd., being investigated for information disclosure violations by the China Securities Regulatory Commission (CSRC) [2][3] Group 1: Regulatory Issues - Tachen International has been formally investigated for information disclosure violations, which is not the first instance of such issues [3] - The company has a history of frequent regulatory penalties, with 21 instances of penalties recorded over the past three years, including issues related to undisclosed agreements and incomplete disclosures [3][4] - The management team, including the chairman and several executives, has faced multiple regulatory warnings, indicating systemic governance issues [3][4] Group 2: Shareholding and Financial Status - Tachen International's shareholding in Tibet Summit has significantly decreased from 38.25% to 7.59% due to judicial freezes and forced sales of shares [6][7] - Recently, 3.5 million shares were sold at a discount, resulting in a transaction price of 9.64 yuan per share, which is approximately 13% lower than the market price [6] - The company has been experiencing declining revenue and profits, with 2024 revenue reported at 1.639 billion yuan and net profit at 230 million yuan, down from 2.049 billion yuan and 715 million yuan in 2021, respectively [7][8] Group 3: Debt and Financial Challenges - Tachen International is embroiled in a debt crisis, with total remaining debts around 1.5 billion yuan, primarily due to multiple loan defaults and legal disputes [7][8] - The company's financial troubles are linked to historical capital operations by the chairman, leading to significant liabilities and subsequent share freezes [7][8] - Despite these challenges, Tibet Summit is advancing its lithium salt project in Argentina, which has received environmental approval and aims to produce 10,000 tons of lithium carbonate annually [8]

Core Viewpoint - The announcement details the regulatory measures and penalties faced by Borui Biopharmaceuticals (Suzhou) Co., Ltd. over the past five years, emphasizing the company's commitment to compliance and governance improvements. Recent Regulatory Penalties - The company and its directors, supervisors, and senior management have not faced any penalties from regulatory authorities in the last five years [1] Recent Regulatory Measures and Rectification - On February 13, 2020, the Shanghai Stock Exchange issued a regulatory work letter regarding the company's announcement on antiviral drug research progress, requiring clarification on the commercialization timeline and potential patent infringements related to the production of remdesivir [2] - The company responded that the remdesivir project is still in the preclinical research stage and that its production is limited to research purposes, thus not infringing on Gilead's patents [2][3] - On March 1, 2020, the Shanghai Stock Exchange issued a decision to place the company under regulatory scrutiny due to unclear information disclosure regarding the distinction between experimental production and commercial production [4] - The former board secretary was criticized for further confusing the terms during a media interview, leading to regulatory actions against him [5] - On March 11, 2020, the Jiangsu Securities Regulatory Bureau issued a warning letter, confirming that the company's disclosure of "batch production" was misleading and did not accurately reflect the drug development progress [7] - On June 30, 2020, the Shanghai Stock Exchange issued a regulatory work letter regarding the establishment of an investment fund, requiring the company to enhance internal control mechanisms and ensure compliance in external investments [8] - On October 17, 2023, a warning letter was issued to an individual for misleading statements regarding a product still in clinical trials, emphasizing the need for accurate information disclosure [9] - On June 20, 2025, a warning letter was issued due to the company's failure to timely redeem idle fundraising cash management products, violating disclosure obligations [10][12] - The company has committed to improving compliance and internal management practices in response to these regulatory measures [11][14]

Core Viewpoint - Beijing Yuanglong Yatu Cultural Communication Co., Ltd. is facing regulatory measures due to information disclosure violations related to fabricated sales activities by an employee [1] Group 1: Regulatory Actions - The Beijing Securities Regulatory Bureau has issued corrective administrative measures against Beijing Yuanglong Yatu, its chairman Sun Zhen, and financial officer Bian Yuchen for information disclosure violations [1] - The company reported to the police regarding an employee's alleged forgery of company seals and sales contracts, which could affect financial statements for sales revenue in 2023, 2024, and the first quarter of 2025 [1] Group 2: Governance Issues - The incident highlights deficiencies in corporate governance and operational compliance within the company [1] - Sun Zhen and Bian Yuchen are held primarily responsible for the company's information disclosure violations [1]